Skip to main content
Erschienen in: Surgery Today 12/2017

22.05.2017 | Original Article

Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease

verfasst von: Nobuyoshi Ohara, Tsunekazu Mizushima, Hideki Iijima, Hidekazu Takahashi, Satoshi Hiyama, Naotsugu Haraguchi, Takahiro Inoue, Junichi Nishimura, Shinichiro Shinzaki, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori

Erschienen in: Surgery Today | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

An elemental diet (ED) can suppress inflammation in patients with Crohn’s disease (CD); however, adherence to this diet is difficult. We examined the correlation between ED adherence and the postoperative recurrence of CD.

Methods

The subjects of this study were 38 patients who underwent intestinal resection with anastomosis. We defined ED adherence as consuming the average daily ED dose (≥900 kcal/day) for 2 years after surgery. Patients who did not adhere to the ED were allocated to the non-ED group. We diagnosed symptomatic recurrence using the CD activity index and endoscopic recurrence using the Rutgeerts’ score.

Results

The ED and non-ED groups comprised 21 and 17 patients, respectively, with ED adherence of 55.3% (21/38). At the initial endoscopy, symptomatic and endoscopic recurrence rates were 4.8 and 14.3%, respectively, in the ED group, and 23.5 and 41.2%, respectively, in the non-ED group (P = 0.152 and P = 0.078, respectively). The overall symptomatic recurrence-free duration was significantly longer than the endoscopic recurrence-free duration (P = 0.022). Symptomatic and endoscopic recurrence-free durations were longer in the ED group than in the non-ED group (P = 0.003 and P = 0.021, respectively), and ED adherence was a prognostic factor for endoscopic recurrence (HR = 2.777, 95% CI = 1.036–8.767, P = 0.042).

Conclusion

Maintaining ED adherence for 2 years after surgery improved the symptomatic and endoscopic recurrence-free durations.
Literatur
1.
Zurück zum Zitat Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25 (Epub 2010/11/26).CrossRefPubMedPubMedCentral Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25 (Epub 2010/11/26).CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Mitsuyama K, Sata M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 2008;12(3):301–12 (Epub 2008/02/14).CrossRefPubMed Mitsuyama K, Sata M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets. 2008;12(3):301–12 (Epub 2008/02/14).CrossRefPubMed
3.
4.
Zurück zum Zitat Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50 (Epub 2002/07/20).CrossRefPubMed Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8(4):244–50 (Epub 2002/07/20).CrossRefPubMed
5.
Zurück zum Zitat Chen M, Yi F, Zhou F, Huang M, Li J, Yan W, et al. Risk factors for initial surgery in patients with Crohn’s disease in Central China. Surg Today. 2015;45(8):1002–8 (Epub 2014/12/20).CrossRefPubMed Chen M, Yi F, Zhou F, Huang M, Li J, Yan W, et al. Risk factors for initial surgery in patients with Crohn’s disease in Central China. Surg Today. 2015;45(8):1002–8 (Epub 2014/12/20).CrossRefPubMed
6.
Zurück zum Zitat Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease—evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25(1):3–12 (Epub 2007/01/19).PubMed Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn’s disease—evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25(1):3–12 (Epub 2007/01/19).PubMed
7.
Zurück zum Zitat Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).CrossRefPubMed Williams JG, Wong WD, Rothenberger DA, Goldberg SM. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78(1):10–9 (Epub 1991/01/01).CrossRefPubMed
8.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63 (Epub 1990/10/01).CrossRefPubMed Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63 (Epub 1990/10/01).CrossRefPubMed
9.
Zurück zum Zitat Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(6):616–20 (Epub 2007/10/31).CrossRefPubMed Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(6):616–20 (Epub 2007/10/31).CrossRefPubMed
10.
Zurück zum Zitat Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73 (Epub 1997/11/14).CrossRefPubMed Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73 (Epub 1997/11/14).CrossRefPubMed
11.
Zurück zum Zitat Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:Cd000067 (Epub 2000/05/05). Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;2:Cd000067 (Epub 2000/05/05).
12.
Zurück zum Zitat Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).CrossRefPubMed Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease. Aliment Pharmacol Ther. 2008;27(1):11–8 (Epub 2007/10/09).CrossRefPubMed
13.
Zurück zum Zitat Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–9 (Epub 1999/09/29).CrossRefPubMed Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117(4):761–9 (Epub 1999/09/29).CrossRefPubMed
14.
Zurück zum Zitat Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).CrossRefPubMed Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333–40 (Epub 2006/10/25).CrossRefPubMed
15.
Zurück zum Zitat Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–21 (Epub 1995/06/01).CrossRefPubMed Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–21 (Epub 1995/06/01).CrossRefPubMed
16.
Zurück zum Zitat Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, et al. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study. Surg Today. 2014;44(2):291–6 (Epub 2013/03/07).CrossRefPubMed Araki T, Uchida K, Okita Y, Fujikawa H, Inoue M, Ohi M, et al. Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study. Surg Today. 2014;44(2):291–6 (Epub 2013/03/07).CrossRefPubMed
17.
Zurück zum Zitat Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, et al. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surg Today. 2016;46(8):922–9 (Epub 2015/10/07).CrossRefPubMed Sumi R, Nakajima K, Iijima H, Wasa M, Shinzaki S, Nezu R, et al. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surg Today. 2016;46(8):922–9 (Epub 2015/10/07).CrossRefPubMed
18.
Zurück zum Zitat Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9 (Epub 2002/06/06).CrossRefPubMed
19.
Zurück zum Zitat Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25 (Epub 2005/11/04).CrossRefPubMed Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25 (Epub 2005/11/04).CrossRefPubMed
20.
Zurück zum Zitat Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83 (Epub 2007/05/09).CrossRefPubMed Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83 (Epub 2007/05/09).CrossRefPubMed
21.
Zurück zum Zitat Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79 (Epub 2004/11/13).CrossRefPubMed Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79 (Epub 2004/11/13).CrossRefPubMed
22.
Zurück zum Zitat Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn’s disease. J Gastroenterol. 1995;30(Suppl 8):83–7 (Epub 1995/11/01).PubMed Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn’s disease. J Gastroenterol. 1995;30(Suppl 8):83–7 (Epub 1995/11/01).PubMed
23.
Zurück zum Zitat Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30(3):322–9 (Epub 1995/06/01).CrossRefPubMed Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30(3):322–9 (Epub 1995/06/01).CrossRefPubMed
24.
Zurück zum Zitat Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25(1):67–72 (Epub 2007/01/19).CrossRefPubMed Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn’s disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007;25(1):67–72 (Epub 2007/01/19).CrossRefPubMed
25.
Zurück zum Zitat Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009;136(2):564-74.e2 (Epub 2008/11/26).CrossRefPubMed Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology. 2009;136(2):564-74.e2 (Epub 2008/11/26).CrossRefPubMed
26.
Zurück zum Zitat Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, et al. Alteration of V beta usage and cytokine production of CD4 + TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol. 2000;165(10):5891–9 (Epub 2000/11/09).CrossRefPubMed Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, et al. Alteration of V beta usage and cytokine production of CD4 + TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol. 2000;165(10):5891–9 (Epub 2000/11/09).CrossRefPubMed
27.
Zurück zum Zitat Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).CrossRefPubMed Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S, et al. Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn’s disease: a prospective study. Inflamm Bowel Dis. 2007;13(12):1493–501 (Epub 2007/09/20).CrossRefPubMed
28.
Zurück zum Zitat Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441-50.e1 (Epub 2008/12/27).CrossRef Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441-50.e1 (Epub 2008/12/27).CrossRef
Metadaten
Titel
Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease
verfasst von
Nobuyoshi Ohara
Tsunekazu Mizushima
Hideki Iijima
Hidekazu Takahashi
Satoshi Hiyama
Naotsugu Haraguchi
Takahiro Inoue
Junichi Nishimura
Shinichiro Shinzaki
Taishi Hata
Chu Matsuda
Hirofumi Yamamoto
Yuichiro Doki
Masaki Mori
Publikationsdatum
22.05.2017
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 12/2017
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-017-1543-5

Weitere Artikel der Ausgabe 12/2017

Surgery Today 12/2017 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.